検索結果

千寿製薬について | 千寿製薬株式会社

CEO Message Management Policy Company Profile Our Initiatives for Society / Environment Business Activities Production system Quality policy

研究開発の取り組み | 千寿製薬株式会社

R & D activities Product Development Policy Research and Development System R & D Pipeline Clinical trial information Publications Meetings of the Minds Business Collaboration Inquiries licens

お知らせ | 千寿製薬株式会社

December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation chann

千寿製薬株式会社

NEWS & RELEASE December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Pot

点眼剤 (1％、2％) <A> イタリア Carteol S.I.F.I. S.p.A. 1988年 点眼剤 (1％、2％) <B> 香港 Arteoptic Otsuka Pharmaceutical (H.K.) Ltd. 1995 年 点眼剤 (1％、2％) <C> 台湾 Arteoptic TAIWAN OTSUKA PHARMACEUTICAL CO...